Analysts' Actions: ADM AMD FDO ISRG STX

TheStreet.com

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Archer-Daniels Midland was upgraded at J.P. Morgan to neutral from underweight. Company should benefit from lower corn prices, J.P. Morgan said.

AIMCO was downgraded at UBS to neutral from buy and given a $32 price target. 2013 same-store sales are unlikely to be raised, and the portfolio is exposed to rising cap rates, UBS said.

Advanced Micro Devices was downgraded at Credit Suisse to underperform from neutral. $3 price target. Profitability continues to be challenging, Credit Suisse said.

Advanced Micro Devices was downgraded at Morgan Stanley to underweight. $2.50 price target. Console margins appear to be lower than previously thought, Morgan Stanley said.

AthenaHealth was downgraded at Lazard Capital Markets to neutral from buy. Valuation call, as the stock has been strong of late, Lazard Capital Markets said.

Cepheid was upgraded at Piper Jaffray to overweight from neutral. Valuation call, based on a $43 price target, Piper Jaffray said.

CYS Investments was downgraded to sell at TheStreet Ratings.

Fairchild Semiconductor was downgraded at FBR Capital Markets to market perform from outperform. $14 price target. Company lowered its guidance, FBR Capital Markets said.

Family Dollar was initiated with a market perform rating at FBR Capital Markets. $64 price target. Consensus estimates appear to be aggressive, FBR Capital Markets said.

Piper Jaffray was downgraded to hold at TheStreet Ratings.

ICU Medical was downgraded at Piper Jaffray to neutral from overweight. $71 price target. Company missed expectations this quarter, but remains a possible takeover target, Piper Jaffray said.

International Game was downgraded at Credit Suisse to underperform from neutral. $16 price target. Core business remains challenged, Credit Suisse said.

Intuitive Surgical was downgraded at JMP Securities to underperform from market perform. $275 price target. Company has received an FDA warning letter and will see no additional reimbursements in Japan next year, JMP Securities said.

Seagate was upgraded at Citigroup to neutral from sell. $49 price target. Industry should see higher profitability, Citigroup said.

Stryker was downgraded at Wunderlich to hold from buy. $71 price target. Company lacks near-term catalysts, Wunderlich said.

Western Digital was upgraded at Citigroup to neutral from sell. $77 price target. Company can exceed near-term earnings expectations, Citi said.

STOCK COMMENTS/EPS CHANGES

Align Technology numbers were boosted at JMP Securities. Shares are now seen reaching $47. Estimates were also raised, given the company's new guidance, JMP Securities said. Outperform rating.

Advanced Micro Devices estimates were raised at UBS. Better-than-expected game console gross margins, said UBS. Price target is $4.50.

AutoNation estimates were raised at UBS. Reflects second-quarter beat, said UBS. Price target is $39.

Apache estimates were reduced at UBS. Reflects the sale of the Gulf of Mexico assets, said UBS. Price target is $92.

BB&T estimates were raised at UBS. Earnings estimates were raised on top-line trends and expense control, said UBS. Price target is $39.

Blackrock estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $288. Estimates were also increased, as the company is seeing higher net inflows, Credit Suisse said. Neutral rating.

Capital One numbers were raised at Oppenheimer. Shares are now seen reaching $78. Estimates were also increased, as the company is seeing higher margins and better credit quality, Oppenheimer said. Outperform rating.

Cepheid estimates were cut at UBS. Reflects margin pressure from manufacturing investments, said UBS. Price target goes to $39.

Community Health numbers were cut at UBS. Weak second quarter and government subpoena, said UBS. Price target goes to $54.

Community Health numbers were reduced at Keybanc. Shares are now seen reaching $54. Estimates were also cut, given lower volume trends and increased bad debt costs, Keybanc said. Buy rating.

Quest Diagnostics numbers were raised at UBS. Increased buybacks, said UBS. Price target increased to $61.

Dover estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $84. Estimates were also increased, after the company delivered an excellent quarter, Credit Suisse said. Neutral rating.

Fifth Third estimates were cut at UBS. Conservative guidance, said UBS. Price target is $21.

Google estimates, price target were cut at Oppenheimer. Estimates were reduced through 2014. Company is realizing lower core operating margins, Oppenheimer said. Perform rating and new $920 price target.

Google numbers were cut at Citi. Estimates were reduced given the weak second-quarter report, said UBS. Price target was cut to $1,005.

Huntington Bancshares numbers were raised at Credit Suisse. Shares are now seen reaching $9.50. Estimates were also increased, given lower loan loss revisions. Outperform rating.

Johnson Controls numbers were raised at UBS. Estimates were increased given traction in turnaround efforts, UBS said. Price target was increased to $41.

Johnson Controls numbers were increased at Deutsche Bank. Estimates were raised through 2014. Company is seeing operating leverage, Deutsche Bank said. Hold rating and new $45 price target.

Keycorp estimates, price target were increased at Credit Suisse. Estimates were boosted through 2015. Company is cutting costs, Credit Suisse said. Neutral rating and new $12.50 price target.

Microsoft estimates were cut at UBS. Estimates were cut given PC headwinds, said UBS. Price target is $40.

Microsoft estimates, price target were cut at Bank of America/Merrill Lynch. Estimates were reduced through 2015. Business shift is hurting margins and cash flow, BofA/Merrill said. Neutral rating and new $36 price target.

Noble estimates, price target were raised at Jefferies. Shares are now seen reaching $43. Estimates were also increased, as operations are improving, Jefferies said. Hold rating.

O'Reilly Automotive numbers were raised at UBS. Estimates were increased as demand remains strong, UBS said. Price target was increased to $131.

Philip Morris numbers were reduced at Jefferies. Estimates were cut through 2014. Estimates were also cut, given an emerging-market slowdown, Jefferies said. Hold rating and new $94 price target.

PPG estimates, price target were increased at Credit Suisse. Estimates were raised through 2015. Core business is trending ahead of expectations, Credit Suisse said. Outperform rating and new $172 price target.

Sherwin-Williams numbers were cut at Citigroup. Shares are now seen reaching $171. Estimates were also reduced, as the Comex acquisition has been blocked in Mexico, Citi said. Neutral rating.

Supervalu estimates, price target were raised at Goldman Sachs. Shares are now seen reaching $8. Estimates were also increased, as the company is realizing higher margins, Goldman Sachs said. Neutral rating.

Skyworks estimates, price target were increased at Lazard Capital Markets. Estimates were raised through 2014. Company is exceeding low expectations, Lazard Capital Markets said. Buy rating and new $31 price target.

UnitedHealth numbers were increased at Oppenheimer. Estimates were boosted through 2014. Company raised its guidance, Oppenheimer said. Outperform rating and new $78 price target.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.

View Comments